ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.25 per share for total gross proceeds of $110 million before deducting underwriting di ...

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis’ innovative late-stage pipeline will be highlighted at Eyecelerator and at the American Academy of Ophthalmology (AAO) Annual Meeting. At Eyecelerator, Riad Sherif, MD, Oculis’ Chief Executive Officer, will provide an updat ...

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis’ innovative late-stage pipeline will be highlighted at Eyecelerator and at the American Academy of Ophthalmology (AAO) Annual Meeting. At Eyecelerator, Riad Sherif, MD, Oculis’ Chief Executive Officer, will provide an update ...

市场潜力 - Privosegtor的市场潜力约为250亿美元，涵盖神经眼科和视网膜适应症[6] - 美国急性视神经炎的年发病率超过3万人，市场潜力约为30亿美元[30][31] - NAION的美国年发病率同样超过3万人，市场潜力约为40亿美元[43][45] - 多发性硬化（MS）相关市场预计超过500亿美元[53] 研发进展 - Privosegtor在急性视神经炎（AON）和非动脉炎前缺血性视神经病（NAION）两项适应症的注册试验将于2025年第四季度和2026年上半年启动[9][16] - AON的PIONEER-1和PIONEER-2注册试验将招募140-160名患者，主要评估在3个月时的视力变化[17][22] - NAION的PIONEER-3注册试验预计在2026年中期启动，旨在建立全球视神经病变的主导项目[9][24] - OCS-01眼药水预计将成为糖尿病性黄斑水肿（DME）的首个非侵入性治疗，注册试验结果预计在2026年第二季度公布[8][50] - Oculis计划在2026年提交DME的NDA申请，进一步推动产品开发[50] - OCS-01若获批准，将成为首个用于糖尿病性黄斑水肿（DME）的局部治疗药物[53] - Licaminlimab作为干眼病（DED）的个性化治疗药物[53] 财务状况 - Oculis的财务状况良好，无债务，现金流可支持到2027年下半年[8] 产品与技术 - Privosegtor的注册试验设计与成功的ACUITY试验相似，采用相同剂量3mg/kg/天[9][24] - Privosegtor在急性视神经炎中的神经保护潜力[53] - Privosegtor在神经眼科及其他领域的市场潜力预计超过250亿美元[53] - Privosegtor在非动脉性前缺血性视神经病（NAION）和多发性硬化（MS）复发中的应用潜力[53] - Privosegtor在多个神经眼科和神经学疾病中的潜在应用[53]

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAION Company to host conference call and webcast at 8:30 AM ET today ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical com ...